Highland Life Sciences: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
Highland Life Sciences
Largest movements
- Current investments -€138,746
down €138,746 (-22.6%), from €615,035 to €476,289
- Other debts -€192,028
down €192,028 (-95.7%), from €200,704 to €8,676
- Reserves +€140,000
up €140,000 (+38.0%), from €368,085 to €508,085
- Tax, wage and social debts -€87,024
down €87,024 (-55.8%), from €156,081 to €69,057
- Financial income +€19,609
up €19,609 (+532%), from €3,689 to €23,298
- Gross operating margin -€16,977
down €16,977 (-8.5%), from €200,018 to €183,041
- Taxes -€2,954
down €2,954 (-4.5%), from €66,218 to €63,265
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €741,514 | €601,142 | -€140,372 | -18.9% |
| Fixed assets | 21/28 | €3,049 | €2,293 | -€756 | -24.8% |
| Tangible fixed assets | 22/27 | €3,049 | €2,293 | -€756 | -24.8% |
| Furniture and vehicles | 24 | €3,049 | €2,293 | -€756 | -24.8% |
| Current assets | 29/58 | €738,465 | €598,849 | -€139,616 | -18.9% |
| Amounts receivable within one year | 40/41 | €45,866 | €41,258 | -€4,608 | -10.0% |
| Trade receivables | 40 | €45,866 | €28,477 | -€17,389 | -37.9% |
| Other amounts receivable | 41 | - | €12,781 | +€12,781 | |
| Current investments | 50/53 | €615,035 | €476,289 | -€138,746 | -22.6% |
| Cash at bank and in hand | 54/58 | €77,425 | €81,302 | +€3,877 | +5.0% |
| Deferred charges and accrued income | 490/1 | €139 | €0 | -€139 | -100% |
| Total equity and liabilities | 10/49 | €741,514 | €601,142 | -€140,372 | -18.9% |
| Equity | 10/15 | €378,993 | €520,572 | +€141,580 | +37.4% |
| Contributions | 10/11 | €2,000 | €2,000 | = | 0.0% |
| Reserves | 13 | €368,085 | €508,085 | +€140,000 | +38.0% |
| Distributable reserves | 133 | €368,085 | €508,085 | +€140,000 | +38.0% |
| Profit (loss) carried forward | 14 | €8,907 | €10,487 | +€1,580 | +17.7% |
| Amounts payable | 17/49 | €362,521 | €80,570 | -€281,951 | -77.8% |
| Amounts payable within one year | 42/48 | €362,521 | €80,570 | -€281,951 | -77.8% |
| Trade debts | 44 | €5,737 | €2,837 | -€2,900 | -50.5% |
| Suppliers | 440/4 | €5,737 | €2,837 | -€2,900 | -50.5% |
| Taxes, remuneration and social security | 45 | €156,081 | €69,057 | -€87,024 | -55.8% |
| Taxes | 450/3 | €156,081 | €69,057 | -€87,024 | -55.8% |
| Other amounts payable | 47/48 | €200,704 | €8,676 | -€192,028 | -95.7% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €731 | €756 | +€25 | +3.4% |
| Other operating charges | 640/8 | €190 | €700 | +€510 | +269% |
| Gross operating margin | 9900 | €200,018 | €183,041 | -€16,977 | -8.5% |
| Operating profit (loss) | 9901 | €199,097 | €181,585 | -€17,512 | -8.8% |
| Financial income | 75/76B | €3,689 | €23,298 | +€19,609 | +532% |
| Recurring financial income | 75 | €3,689 | €23,298 | +€19,609 | +532% |
| Financial charges | 65/66B | €68 | €39 | -€29 | -43.0% |
| Recurring financial charges | 65 | €68 | €39 | -€29 | -43.0% |
| Profit (loss) for the period before taxes | 9903 | €202,718 | €204,845 | +€2,126 | +1.0% |
| Income taxes | 67/77 | €66,218 | €63,265 | -€2,954 | -4.5% |
| Profit (loss) for the period | 9904 | €136,500 | €141,580 | +€5,080 | +3.7% |
| Profit (loss) for the period to be appropriated | 9905 | €136,500 | €141,580 | +€5,080 | +3.7% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 14 October 2026 via checked.be.